Abstract
The stubbornly high incidence of new HIV infections belies the overwhelming evidence showing that sustained highly active antiretroviral therapy (HAART) has the power to dramatically reduce the spread of HIV infection and forever change the face of this devastating epidemic. One of the main contributors to this public health paradox is the ongoing HIV epidemic among substance users who contribute significantly to HIV infection rates through injection drug use and high-risk sexual behaviours. Current evidence clearly shows that, in order to fill this gap, we need to integrate substance abuse treatment with HIV treatment programmes and provide substance abusers with universal access to HIV treatment through a focussed effort to seek, test, treat, and retain hard-to-reach high risk individuals. These aims will require structural changes in the health care system to overcome many of the obstacles that have inhibited the merging of substance abuse treatment with HIV programmes for far too long.
Keywords: HAART, highly active antiretroviral therapy, HIV prevention, substance use disorders, treatment, opioid addiction, Disease Control and Prevention, opiate replacement therapy, hypothesis
Current HIV Research
Title: The Unrealized Potential of Addiction Science in Curbing the HIV Epidemic
Volume: 9 Issue: 6
Author(s): Nora D. Volkow, Ruben D. Baler and Jacques L. Normand
Affiliation:
Keywords: HAART, highly active antiretroviral therapy, HIV prevention, substance use disorders, treatment, opioid addiction, Disease Control and Prevention, opiate replacement therapy, hypothesis
Abstract: The stubbornly high incidence of new HIV infections belies the overwhelming evidence showing that sustained highly active antiretroviral therapy (HAART) has the power to dramatically reduce the spread of HIV infection and forever change the face of this devastating epidemic. One of the main contributors to this public health paradox is the ongoing HIV epidemic among substance users who contribute significantly to HIV infection rates through injection drug use and high-risk sexual behaviours. Current evidence clearly shows that, in order to fill this gap, we need to integrate substance abuse treatment with HIV treatment programmes and provide substance abusers with universal access to HIV treatment through a focussed effort to seek, test, treat, and retain hard-to-reach high risk individuals. These aims will require structural changes in the health care system to overcome many of the obstacles that have inhibited the merging of substance abuse treatment with HIV programmes for far too long.
Export Options
About this article
Cite this article as:
D. Volkow Nora, D. Baler Ruben and L. Normand Jacques, The Unrealized Potential of Addiction Science in Curbing the HIV Epidemic, Current HIV Research 2011; 9 (6) . https://dx.doi.org/10.2174/157016211798038605
DOI https://dx.doi.org/10.2174/157016211798038605 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Stable Gastric Pentadecapeptide BPC 157-NO-system Relation
Current Pharmaceutical Design Pin1: A New Genetic Link between Alzheimer’s Disease, Cancer and Aging
Current Aging Science Genetic Variation and Atherosclerosis
Current Genomics Modulation of Gut-Brain Axis by Probiotics: A Promising Anti-depressant Approach
Current Neuropharmacology Clinical Applications and Biosafety of Human Adult Mesenchymal Stem Cells
Current Pharmaceutical Design Nicotine-Derived Compounds as Therapeutic Tools Against Post-Traumatic Stress Disorder
Current Pharmaceutical Design Microarray Data Analysis to Find Diagnostic Approach and Identify Families of Disease-Altered Genes Based on Rank-Reverse of Gene Expression
Current Bioinformatics Editorial [Hot Topic:Role of Neural Stem Cells in Neurodegenerative Diseases:From the Molecule and Cell to the Clinic (Guest Editor: Oscar Gonzalez-Perez)]
Current Signal Transduction Therapy Mucosal Vaccination for Prevention of HIV Infection and AIDS
Current HIV Research Adolescent Peer Victimization and PTSD Risk
Adolescent Psychiatry A Potential Role for the Existence of Pericytes in the Neurovascular Unit of the Sexually Dimorphic Nucleus of the Rat Preoptic Area to Control Blood-Brain Barrier Function
Current Neurovascular Research Editorial (Thematic Issue: The Activity of Products From Cnidaria: A Therapeutic Tool in Neurological Diseases? Part II)
Central Nervous System Agents in Medicinal Chemistry Social Determinants, Race, and Brain Health Outcomes: Findings from the Chicago Health and Aging Project
Current Alzheimer Research Hypocholesterolemia
Current Vascular Pharmacology Male and Female Rats Differ in Brain Cannabinoid CB1 Receptor Density and Function and in Behavioural Traits Predisposing to Drug Addiction: Effect of Ovarian Hormones
Current Pharmaceutical Design Chronic Inflammatory Diseases: Progress and Prospect with Herbal Medicine
Current Pharmaceutical Design N-3 (Omega-3) Polyunsaturated Fatty Acids in the Pathophysiology and Treatment of Depression: Pre-Clinical Evidence
CNS & Neurological Disorders - Drug Targets Safety Analysis and Improved Cardiac Function Following Local Autologous Transplantation of CD133+ Enriched Bone Marrow Cells After Myocardial Infarction
Current Neurovascular Research Clinical Relevance of Apolipoprotein E Genotyping Based on a Family History of Alzheimer's Disease
Current Alzheimer Research Effect of Different Aβ Aggregates as Antigen on the Measure of Naturally Occurring Autoantibodies against Amyloid-β40/42 in IVIG
Current Alzheimer Research